Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
A recent study conducted in Iceland has revealed that approximately 4% of the population carries at least one actionable genotype, which is associated with a reduced life span.
All Specialties November 15th 2023
MDLinx
Discover how a study from USC reveals that the most common genetic cause of ALS and FTD may have its roots in embryonic development, offering new avenues for early diagnosis and treatment.
Neurology August 30th 2023
Dana-Farber Cancer Institute
Explore the potential of OncoNPC, an AI model that leverages gene sequencing data to predict the primary source of cancer, offering a new avenue for more targeted and effective treatments.
Hematology/Oncology August 29th 2023
Cancer Therapy Advisor
Explore the complexities of treating small cell lung cancer (SCLC) after platinum-based therapy failure, including insights into immune checkpoint inhibitors, the preference for lurbinectedin, and the potential of liquid biopsies. Join Dr. Misty Shields in understanding the challenges and opportunities in this evolving field.
Oncology, Medical August 21st 2023
OBR Oncology
The recent study on MCL reveals a promising approach in identifying high-risk patients through the combination of MIPI-c and p53 overexpression. This method may guide the development of targeted therapies and personalized treatment plans, addressing the unmet needs of those at the highest risk.
Hematology/Oncology August 21st 2023
Northwestern Medicine
Discover the pioneering research connecting marijuana use with modifications in the human epigenome. The study brings to light potential health implications and illuminates areas for future exploration.
Psychiatry July 26th 2023